Showing 6991-7000 of 19322 results for "".
Advancing Heart Failure Treatment With Barostim: An Electrophysiologist’s Real-World Success Story
https://reachmd.com/programs/cme/advancing-heart-failure-treatment-with-barostim-an-electrophysiologists-real-world-success-story/29821/Dr. Verma provides expert guidance based on real-world data and personal experience to help you ensure successful use of the Barostim device.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence
https://reachmd.com/programs/cme/mechanisms-pressure-relief-glaucoma-pharmacologic-surgical-advances-refractory-poag-or-non-adherence/9931/Glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension.PH Management in Unique Patients and Conditions
https://reachmd.com/programs/cme/ph-management-in-unique-patients-and-conditions/36096/Experts discuss addressing challenges that may come with managing patients with pulmonary hypertension (PH) in unique patient populations and with complex conditions.ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive YearsAdditional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
https://reachmd.com/clinical-practice/oncology-hematology/additional-safey-data-from-tropion-breast02-and-study-design-of-tropion-breast06/49125/Learn how TROPION-Breast02 and TROPION-Breast06 are shaping the role of Dato-DXd in mTNBC and chemo-naïve HR+/HER2- mBC, respectively.Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
https://reachmd.com/programs/cme/secondary-hyperparathyroidism-a-hidden-danger-in-chronic-kidney-disease/14973/How can you diagnose patients with SHPT earlier in CKD and control PTH levels early in the disease course? Our experts have what you need to know!Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
https://reachmd.com/programs/cme/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/Tune in to explore age-related diagnostic considerations and confirmation strategies for generalized myasthenia gravis.Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies
https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/How can you use emerging therapeutic options to treat patients with autosomal dominant polycystic kidney disease?Second Ebola Virus Treatment Approved
https://reachmd.com/programs/the-drug-report/second-ebola-virus-treatment-approved/12120/The FDA announced approval for a second ebolavirus treatment nearly seven years after the largest Ebola epidemic in West Africa.